List view / Grid view
19 October 2015 | By Victoria White
Praxbind is indicated for patients treated with Pradaxa, when reversal of the anticoagulant effects of Pradaxa is needed for emergency surgery or in uncontrolled bleeding...
13 October 2015 | By Victoria White
Cinryze is being studied as an adjunct treatment to Donor Specific Antibodies (DSA) reduction therapy in kidney transplant patients with acute antibody mediated rejection...
8 October 2015 | By Victoria White
The FDA has granted Breakthrough Therapy Designation to abemaciclib for patients with refractory HR+ advanced or metastatic breast cancer...
8 October 2015 | By Victoria White
The exclusivity ensures that the FDA will not approve any applications for biosimilars of the drug before July 2026...
7 October 2015 | By Victoria White
Aristada is the first atypical antipsychotic with once-monthly and six-week dosing options for delivering and maintaining therapeutic levels of medication in the body through an injection...
6 October 2015 | By Victoria White
The applications are for the treatment of patients with chronic HCV coinfected with HIV-1, patients with advanced cirrhosis, and for patients with post-liver transplant recurrence of HCV...
5 October 2015 | By Victoria White
The combination is approved to reduce the risks of disease progression and hospitalisation for worsening PAH, and to improve exercise ability...
5 October 2015 | By Victoria White
Keytruda is now the first and only anti-PD-1 ((programmed death receptor-1) therapy approved for both squamous and non-squamous metastatic NSCLC...
22 September 2015 | By Victoria White
The FDA awards the grants through the Orphan Products Grants Programme to encourage clinical development of treatments for use in rare diseases...
16 September 2015 | By Victoria White
It is approved by the FDA for the long-term, once-daily, maintenance treatment of asthma in patients 12 years of age and older...
16 September 2015 | By Victoria White
The designation is based on results of CheckMate -025, a Phase 3 study that evaluated the survival of patients with previously treated advanced or metastatic clear-cell RCC versus everolimus...
16 September 2015 | By Victoria White
Nuwiq is the first B-domain deleted recombinant Factor VIII derived from a human cell-line designed for the treatment of patients with haemophilia A...
14 September 2015 | By Victoria White
A supplemental New Drug Application (sNDA) for Imbruvica (ibrutinib) has been submitted to the US Food and Drug Administration (FDA) for front-line use in patients with chronic lymphocytic leukaemia (CLL).
The US Food and Drug Administration (FDA) has approved AbbVie’s Humira (adalimumab) for the treatment of moderate to severe hidradenitis suppurativa.
11 September 2015 | By Victoria White
Allergan has said that its partner, Perrigo, will begin shipments of the products to its retail and wholesale customers in the US in time for the 2016 cough and cold season...
